[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560279":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":37,"centralContacts":41,"locations":47,"responsibleParty":64,"collaborators":68,"id":72,"slug":36,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":36,"studyType":85,"phases":86,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":50,"whyStopped":36,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Stanford University","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"0.25 mg\u002Fkg RR-HNK","EXPERIMENTAL","OCD patients in this arm will receive 0.25mg\u002Fkg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[13],"Drug: RR-HNK\u002FHydroxynorketamine",{"label":15,"type":10,"description":16,"interventionNames":17},"0.5 mg\u002Fkg RR-HNK","OCD patients in this arm will receive 0.5mg\u002Fkg of RR-HNK - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"Placebo (Sterile Saline)","PLACEBO_COMPARATOR","OCD patients in this arm will receive sterile saline - one single infusion. EEG and computerized behavioral tests will be acquired before and after infusion.",[23],"Drug: Placebo",[25,32],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","RR-HNK\u002FHydroxynorketamine","(2R,6R)-Hydroxynorketamine is a metabolite of the drug ketamine and a glutamate AMPA receptor antagonist.",[9,15],[31],"(2R,6R)-Hydroxynorketamine",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Placebo","Sterile Saline",[19],null,[38],{"name":39,"affiliation":5,"role":40},"Carolyn Rodriguez, MD, PhD","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":36,"email":46},"Izzy Vo, BS","CONTACT","650-723-4095","ocdresearch@stanford.edu",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Stanford University School of Medicine","RECRUITING","Palo Alto","California","94305","United States",{"type":56,"coordinates":57},"Point",[58,59],-122.14302,37.44188,{"lat":59,"lon":58},[62],{"name":63,"role":44,"phone":36,"phoneExt":36,"email":36},"Daniel Bello, BS",{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Carolyn Rodriguez","Professor",[69],{"name":70,"class":71},"National Institutes of Health (NIH)","NIH","100560279",false,"NCT06575075","Pilot Study of RR-HNK in OCD","A Double-blind, Placebo-controlled Study to Determine the Safety and Feasibility of Two Doses of Intravenous (2R, 6R)-Hydroxynorketamine (RR-HNK) in Adults With Obsessive-Compulsive Disorder","(HNKO)","Inclusion Criteria:\n\n* Ages 18-65\n* Meet the criteria for OCD diagnosis\n* Failed at least 1 prior trial of standard first-line OCD treatment (e.g. SRI\u002FCBT) or or had refused these treatments for individual reasons\n* Agree to the following lifestyle modifications: comply with requirements for fasting prior to --the infusion session, not enroll in any other interventional clinical trials during the duration of the study, and commit to medication study procedures.\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to ketamine\n* Any current or past medical\u002Fpsychiatric condition that makes participation unsafe in the opinion of the investigator or study physician\n* Pregnant or nursing, or able to become pregnant and are not practicing an effective means of birth control\n* Lifetime history of deep brain stimulation","ALL","18 Years","65 Years",{"count":83,"type":84},45,"ESTIMATED","INTERVENTIONAL",[87,88],"PHASE1","PHASE2","The purpose of this study is to understand how RR-HNK works in the brain to bring about a reduction in OCD symptoms.",[91],"Obsessive-Compulsive Disorder",[93,94,95,96],"OCD","AMPA receptor antagonist","hydroxynorketamine","ketamine metabolite","2026-03-03",{"date":99,"type":100},"2026-03-05","ACTUAL",{"date":102,"type":100},"2026-01-23",{"date":104,"type":84},"2029-11-30",{"name":66,"class":6},1]